阿昔莫司胶囊联合绞股蓝总甙片治疗以甘油三酯升高为主的混合型高脂血症的疗效观察

禹振霞

【摘要】 目的 觀察阿昔莫司胶囊联合绞股蓝总甙片治疗以甘油三酯升高为主的混合型高脂血症的疗效。方法 36例以甘油三酯升高为主的混合型高脂血症患者， 随机分成治疗组及对照组， 各18例。治疗组应用阿昔莫司胶囊联合绞股蓝总甙片治疗， 对照组应用辛伐他汀片治疗。观察比较两组治疗效果及不良反应发生情况。结果 治疗前， 两组患者的甘油三酯、 总胆固醇、 低密度脂蛋白胆固醇比较， 差异均无统计学意义（t=0.177、0.033、0.309， P>0.05）；治疗后， 治疗组的甘油三酯低于对照组， 差异具有统计学意义 （t=2.949， P<0.05） ；两组患者的总胆固醇及低密度脂蛋白胆固醇比较， 差异均无统计学意义（t=0.244、0.315， P>0.05）。治疗后， 治疗组2型糖尿病患者的空腹血糖（6.5±1.4）mmol/L低于对照组2型糖尿病患者（8.0±1.7）mmol/L， 差异具有统计学意义（P<0.05）。治疗组无一例发生不良反应， 对照组发生1例（5.6%）， 两组比较差异无统计学意义（P>0.05）。结论 阿昔莫司胶囊联合绞股蓝总甙片治疗以甘油三酯升高为主的混合型高脂血症疗效确切， 并使糖尿病合并混合型高脂血症患者的血糖降低。

【关键词】 阿昔莫司胶囊；绞股蓝总甙片；混合型高脂血症

DOI：10.14163/j.cnki.11-5547/r.2017.02.046

Observation on curative effect of acipimox capsules combined with Jiaogulanzongdai tablets for the treatment of mixed hyperlipaemia mainly on elevated triglycerides YU Zhen-xia. Beijing City Daxing District Huangcun Hospital， Beijing 102600， China

【Abstract】 Objective To observe the curative effect of acipimox capsules combined with Jiaogulanzongdai tablets for the treatment of mixed hyperlipaemia mainly on elevated triglycerides. Methods A total of 36 patients with mixed hyperlipaemia mainly on elevated triglycerides were randomly divided into treatment group and control group， with 18 cases in each group. The treatment group received acipimox capsules combined with Jiaogulanzongdai tablets for treatment， and the control group received simvastatin tablets for treatment. Treatment effect was observed and compared in two groups. Results There were no statistically significant difference in triglyceride， total cholesterol and low-density lipoprotein cholesterol before treatment in two groups （t=0.177， 0.033， 0.309， P>0.05）. After treatment， the treatment group had lower triglyceride than that in the control group， and the difference had statistical significance （t=2.949， P<0.05）. There were no statistically significant difference in total cholesterol and low-density lipoprotein cholesterol in two groups （t=0.244， 0.315， P>0.05）. After treatment， the treatment group had lower fasting blood-glucose in type 2 diabetes mellitus patients as （6.5±1.4） mmol/L than （8.0±1.7） mmol/L in the control group， and the difference had statistical significance （P<0.05）. The treatment group had 0 adverse reaction case， while the control group had 1 adverse reaction case， and their difference had no statistical significance （P>0.05）. Conclusion Combined treatment of acipimox capsules and Jiaogulanzongdai tablets shows affirmative curative effect for the treatment of mixed hyperlipaemia mainly on elevated triglycerides. It also lower blood glucose of patients with diabetes complicated with mixed hyperlipidemia.